Quest Diagnostics stock rises after cancer test gains New York approval

Quest Diagnostics stock rose after its cancer detection test received New York state approval. The Haystack MRD test, a liquid biopsy for solid tumors, is now available nationwide. New York's approval was the final state requirement for its widespread use. The test aims to detect residual disease and recurrence earlier than imaging methods, potentially improving patient management.